553 related articles for article (PubMed ID: 23532686)
1. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
Patrick J; Dillaha L; Armas D; Sessa WC
Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antiplatelet effects of clopidogrel plus acetylsalicylic acid compared with acetylsalicylic acid alone or combined with extended-release dipyridamole in healthy volunteers.
Caplain H
Cerebrovasc Dis; 2005; 19(4):214-9. PubMed ID: 15703464
[TBL] [Abstract][Full Text] [Related]
5. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
Gurbel PA; Bliden KP; Fort JG; Jeong YH; Shuldiner A; Chai S; Gesheff T; Antonino M; Gesheff M; Zhang Y; Tantry US
Am Heart J; 2013 Feb; 165(2):176-82. PubMed ID: 23351820
[TBL] [Abstract][Full Text] [Related]
6. Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Andersson T; Nagy P; Niazi M; Nylander S; Galbraith H; Ranjan S; Wallentin L
Am J Cardiovasc Drugs; 2014 Jun; 14(3):217-27. PubMed ID: 24677117
[TBL] [Abstract][Full Text] [Related]
7. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
8. The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Uchiyama S; Ikeda Y; Urano Y; Horie Y; Yamaguchi T
Cerebrovasc Dis; 2011; 31(6):601-13. PubMed ID: 21502757
[TBL] [Abstract][Full Text] [Related]
9. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
[TBL] [Abstract][Full Text] [Related]
11. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
[TBL] [Abstract][Full Text] [Related]
12. Aggrenox: a fixed-dose combination of aspirin and dipyridamole.
Lenz TL; Hilleman DE
Ann Pharmacother; 2000 Nov; 34(11):1283-90. PubMed ID: 11098344
[TBL] [Abstract][Full Text] [Related]
13. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, single-dose crossover study.
Jung JA; Kim TE; Kim JR; Kim MJ; Huh W; Park KM; Lee SY; Ko JW
Clin Ther; 2013 Jul; 35(7):985-94. PubMed ID: 23870608
[TBL] [Abstract][Full Text] [Related]
15. Dipyridamole bioavailability in subjects with reduced gastric acidity.
Derendorf H; VanderMaelen CP; Brickl RS; MacGregor TR; Eisert W
J Clin Pharmacol; 2005 Jul; 45(7):845-50. PubMed ID: 15951475
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers.
Andersson T; Morrison D; Nagy P; Pisupati J; Schettler J; Warner TD
Am J Cardiovasc Drugs; 2012 Aug; 12(4):217-24. PubMed ID: 22631032
[TBL] [Abstract][Full Text] [Related]
17. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
[TBL] [Abstract][Full Text] [Related]
18. Dose titration to reduce dipyridamole-related headache.
Chang YJ; Ryu SJ; Lee TH
Cerebrovasc Dis; 2006; 22(4):258-62. PubMed ID: 16788299
[TBL] [Abstract][Full Text] [Related]
19. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Shah H; Gondek K
Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
[TBL] [Abstract][Full Text] [Related]
20. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
Miner PB; Fort JG; Zhang Y
Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
